Published: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 151 to 175 of 797

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Tezepelumab for treating severe asthma	TA880	20 April 2023	20 April 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)	TA879	6 April 2023	6 April 2023
Finerenone for treating chronic kidney disease in type 2 diabetes	TA877	23 March 2023	23 March 2023
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer	TA876	22 March 2023	22 March 2023
Eptinezumab for preventing migraine	TA871	1 March 2023	1 March 2023
Cannabidiol for treating seizures caused by tuberous sclerosis complex	TA873	1 March 2023	1 March 2023
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma	TA874	1 March 2023	1 March 2023
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies	TA872	28 February 2023	28 February 2023
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma	TA870	22 February 2023	22 February 2023
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)	TA867	16 February 2023	16 February 2023
Vutrisiran for treating hereditary transthyretin-related amyloidosis	TA868	15 February 2023	15 February 2023
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma	TA865	8 February 2023	8 February 2023
Regorafenib for previously treated metastatic colorectal cancer	TA866	8 February 2023	8 February 2023
Upadacitinib for treating active non-radiographic axial spondyloarthritis	TA861	1 February 2023	1 February 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments	TA862	1 February 2023	1 February 2023
Somatrogon for treating growth disturbance in children and young people aged 3 years and over	TA863	1 February 2023	1 February 2023
Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted	TA864	1 February 2023	1 February 2023
Maribavir for treating refractory cytomegalovirus infection after transplant	TA860	18 January 2023	18 January 2023
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)	TA859	16 January 2023	16 January 2023
Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma	TA857	11 January 2023	11 January 2023
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma	TA858	11 January 2023	11 January 2023
Upadacitinib for treating moderately to severely active ulcerative colitis	TA856	4 January 2023	4 January 2023
Avatrombopag for treating primary chronic immune thrombocytopenia	TA853	15 December 2022	15 December 2022
Cabozantinib for previously treated advanced hepatocellular carcinoma	TA849	14 December 2022	14 December 2022
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy	TA850	14 December 2022	14 December 2022

Results per page

10
25
50
All